Charles Schwab’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Charles Schwab’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-265,763	Closed	-$12.3M	–	3689
2023 Q2	$12.3M	Buy	265,763 +10,211	+4%	+$353K	﹤0.01%	1811
2023 Q1	$7.32M	Buy	255,552 +2,275	+0.9%	+$67.4K	﹤0.01%	2021
2022 Q4	$7.9M	Buy	253,277 +64,601	+34%	+$2.11M	﹤0.01%	1985
2022 Q3	$3.83M	Buy	188,676 +64,871	+52%	+$1.18M	﹤0.01%	2359
2022 Q2	$1.92M	Buy	123,805 +28,724	+30%	+$494K	﹤0.01%	2575
2022 Q1	$1.82M	Buy	95,081 +2,937	+3%	+$52.4K	﹤0.01%	2677
2021 Q4	$2.33M	Buy	+92,144	New	+$2.7M	﹤0.01%	2649

Charles Schwab's DICE Position: Q3 2023 in Review

Charles Schwab sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 265,763 shares — an estimated $12.3M sold.

Charles Schwab first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $12.3M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Charles Schwab reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Charles Schwab sold 265,763 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $12.3M.
Charles Schwab first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Charles Schwab's DICE Therapeutics, Inc. Common Stock position peaked at $12.3M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.